Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 in Advanced Renal Cell Carcinoma
NCT01141569Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RO4929097 in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 12 months. Started Jun 2010; status: completed.
02
Drugs
RO4929097
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01141569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01141569.